The first participant has received a groundbreaking gene therapy designed to reverse the ageing process in cells, specifically targeting retinal cells to potentially restore vision. The therapy, part of a highly anticipated clinical trial, aims to make aged cells behave as if they were young again, according to the Guardian's science editor Ian Sample.
How the therapy works
The treatment focuses on cellular rejuvenation, an emerging field that seeks to reprogram cells to a more youthful state. In this trial, the therapy is delivered to retinal cells in the eye, with the hope that rejuvenating these cells will improve sight in patients with age-related vision loss. Paul Knoepfler, professor of cell biology and human anatomy at the University of California, Davis, explained the significance: "This is a first-in-human trial that could pave the way for a new class of anti-ageing treatments."
Potential impact and next steps
If the trial proves safe, it could open the door to a range of therapies based on cellular rejuvenation for other age-related conditions. The researchers are closely monitoring the first participant for safety and efficacy signals. The trial represents a major step in translating laboratory discoveries into clinical applications for ageing.
